Diagnosis and management of Waldenstrom's macroglobulinemia

Journal of Clinical Oncology

Volumn 23, Issue 7, 2005, Pages 1564-1577

  Dimopoulos, Meletios A ^a   Kyle, Robert A ^a   Anagnostopoulos, Athanasios ^a   Treon, Steven P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; BORTEZOMIB; CARMUSTINE; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; LENALIDOMIDE; MELPHALAN; NITROSOUREA; OBLIMERSEN; PENTOSTATIN; PREDNISONE; RITUXIMAB; SILDENAFIL; THALIDOMIDE; UNINDEXED DRUG; VACCINE; VINCA ALKALOID; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHILL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIAGNOSTIC PROCEDURE; DISEASE MANAGEMENT; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG WITHDRAWAL; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; LABORATORY TEST; LEUKEMIA; LOW DRUG DOSE; LYMPHOMA; LYMPHOPLASMACYTOID LYMPHOMA; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASIA; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SPLENECTOMY; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION; BLOOD; STEM CELL TRANSPLANTATION;

ALKYLATING AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULIN M; INTERFERON-ALPHA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 14944377069     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.144     Document Type: Review

References (113)

1. Waldenstrom J: Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia: A new syndrome? Acta Med Scand 117:216-222, 1944
2. Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldnestrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:110-115, 2003
3. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International lymphoma Study Group. Blood 84:1361-1392, 1994
4. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
5. Remstein ED, Hanson CA, Kyle RA, et al: Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes and plasma cells. Semin Oncol 30:182-186, 2003
6. San Miguel JF, Vidriales MB, Oci OE, et al: Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 30:187-195, 2003
7. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000
8. Kyle RA, Therneau TM, Rajkumar SV, et al: Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102:3759-3765, 2003
9. Kyle RA, Carton JP: The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 62:719-731, 1987
10. Dimopoulos MA, Alexanian R: Waldenstrom's macroglotaulinemia. Blood 83:1452-1459, 1994
11. Fudenberg HH, Virella G: Multiple myeloma and Waldenstrom macroglobulinemia: Unusual presentations. Semin Hematol 17:63-79, 1980
12. Lin P, Buesco-Ramos C, Wilson CS, et al: Waldenstrom macroglobulinemia involving extramedullary sites. Am J Surg Pathol 27:1104-1113, 2003
13. Fadil A, Taylor DE: The lung and Waldenstrom's macroglobulinemia. South Med J 91:681-685, 1998
14. Veltman GA, Van Veen S, Kluin-Nelemans JC, et al: Renal disease in Waldenstrom's macroglobulinemia. Nephrol Dial Transplant 12:1256-1259, 1997
15. Daoud MS, Lust JA, Kyle RA: Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol 40:507-535, 1999
16. Ovellama J, Friedman AH: Ocular manifestations of multiple myeloma, Waldenstrom's macroglobulinemia and benign monoclonal gammopathy. Surv Ophthalmol 26:157-169, 1981
17. Civit T, Coulbois S, Baylac F, et al: Waldenstrom's macroglobulinemia and cerebral lymphoplasmacytic proliferation: Bing and Neel syndrome-Apropos of a new case. Neurochirurgie 43:245-249, 1997
18. Kwann HC, Bongu A: The hyperviscosity syndromes. Semin Thromb Hemost 25:199-208, 1999
19. Farhangi M, Merlini G: The clinical implications of monoclonal immunoglobulins. Semin Oncol 13:366-379, 1986
20. Case Records of the Massachusetts General Hospital: Weekly clinicopathological exercises: Case 3-1990-A 66-year-old woman with Waldenstrom's macroglobulinemia, diarrhea, anemia and persistent gastrointestinal bleeding. N Engl J Med 322:183-192, 1990
21. Gertz MA, Kyle RA, Noel P: Primary systemic amyloidosis: A rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol 11:914-920, 1993
22. Gertz MA, Kyle RA: Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 30:325-328, 2003
23. Gardyn J, Schwartz A, Gal R, et al: Waldenstrom's macroglobulinemia associated with AA amyloidosis. Int J Hematol 74:76-78, 2001
24. Ropper AH, Gorson KC: Neuropathies associated with paraproteinemia. N Engl J Med 338:1601-1607, 1998
25. Vital A: Paraproteinemic neuropathies. Brain Pathol 11:399-407, 2001
26. Crisp D, Pruzanski W: B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 72:915-922, 1982
27. Lindstrom FD, Hed J, Enestrom S: Renal pathology of Waldenstrom's macroglobulinemia with monoclonal antiglomerular antibodies and nephritic syndrome. Clin Exp Immunol 41:196-204, 1980
28. Sen HN, Chan CC, Caruso RC, et al: Waldenstrom's macroglobulinemia- associated retinopathy. Ophthalmology 111:535-539, 2004
29. Kyle RA, Treon SP, Alexanian R, et al: Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:116-120, 2003
30. Alexanian R, Weber D, Delasalle K, et al: Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30:206-210, 2003
31. Cesana C, Miqueleiz S, Bernuzzi P, et al: Smouldering Waldenstrom's macroglobulinemia: Factors predicting evolution to symptomatic disease. Semin Oncol 30:231-236, 2003
32. Gobbi PG, Bettini R, Montecucco C, et al: Study of prognosis in Waldenstrom's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility. Blood 83:2939-2945, 1994
33. Morel P, Monconduit M, Jacomy D, et al: Prognostic factors in Waldenstrom macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852-858, 2000
34. Garcia-Sanz R, Montoto S, Torrequebrada A, et al: Waldenstrom macroglobulinemia: Presenting features and outcome in a series with 217 cases. Br J Haematol 115:575-582, 2001
35. Owen RG, Barrans SL, Richards SJ, et al: Waldnestrom macroglobulinemia: Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 116:420-428, 2001
36. Dimopoulos MA, Hamilos G, Zervas K, et al: Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 14:1299-1305, 2003
37. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SWOG 5903). Semin Oncol 30:220-225, 2003
38. Merlini G, Baldini L, Broglia C, et al: Prognostic factors in Waldenstrom's macroglobulinemia. Semin Oncol 30:211-215, 2003
39. Ghobrial IM, Fonseca R, Gertz MA, et al: Prognostic model for disease specific and overall mortality in 410 newly diagnosed patients with Waldenstrom macroglobulinemia. 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 52
40. Dimopoulos MA, Gika D, Zervas K, et al: The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia. Leuk Lymphoma 45:1809-1813, 2004
41. Weber D, Treon SP, Emmanouilides C, et al: Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendation from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:127-131, 2003
42. Kyle RA, Greipp PR, Gertz MA, et al: Waldenstrom's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742, 2000
43. Leblond V, Levy V, Maloisel F, et al: Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98:2640-2644, 2001
44. Kaplan AA: Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. Ther Apher 5:171-175, 2001
45. Zarkovic M, Kwaan HC: Correction of hyperviscosity by apheresis. Semin Thromb Hemost 29:535-542, 2003
46. Buskard NA, Galton DAG, Goldman JM, et al: Plasma exchange in the long-term treatment of Waldenstrom's macroglobulinemia. Can Med Assoc J 117:135-137, 1977
47. Dyck PJ, Low PA, Windebank AJ, et al: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325:1482-1486, 1991
48. Latov N: Prognosis of neuropathy with monoclonal gammopathy. Muscle Nerve 23:150-152, 2000
49. Dispenzieri A: Symptomatic cryoglobulinemia. Curr Treat Options Oncol 1:105-118, 2000
50. Cavanna L, Berte R, Lazzaro A, et al: Advanced Waldenstrom's macroglobulinemia: A case of possible cure after systemic chemotherapy, splenic radiation, and splenectomy. Acta Haematol 108:97-101, 2002
51. Foran JM, Rohatiner AZ, Coiffier B, et al: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546-553, 1999
52. Dimopoulos MA, Kantarjian H, Weber D, et al: Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-2698, 1994
53. Fridrik MA, Jager G, Baldinger C, et al: First-line treatment of Waldenstrom's disease with cladribine. Ann Hematol 74:7-10, 1997
54. Hellmann A, Lewandowski K, Zaucha JM: Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol 63:35-41, 1999
55. Delannoy A, Van de Neste E, Michaux JL, et al: Cladribine for Waldenstrom's macroglobulinemia. Br J Haematol 104:933-934, 1999
56. Hampshire A, Saven A: Update of bolus administration of cladribine in the treatment of Waldenstrom's macroglobulinemia. Blood 102:402a, 2003 (abstr)
57. Dimopoulos MA, O'Brien S, Kantarjian H, et al: Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 95:49-52, 1993
58. Leblond V, Ben-Othman T, Deconinck E, et al: Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: A report of 71 cases-Group Cooperatif Macroglobulinemie. J Clin Oncol 16:2060-2064, 1998
59. Dimopoulos MA, Weber D, Delasalle KB, et al: Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors. Ann Oncol 6:49-52, 1995
60. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al: Cladribine (2-CDA) given as subcutaneous bolus injection is active in pretreated Waldenstrom's macroglobulinemia: Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 99:358-363, 1997
61. Dimopoulos MA, Weber DM, Kantarjian H, et al: 2-Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann Oncol 5:288-289, 1994
62. Case DC, Ervin TJ, Boyd MA: Long term results and disease characteristics of patients with Waldenstrom's macroglobulinemia treated with the M-2 protocol. Blood 82:561a, 1993 (abstr 2230)
63. Petrucci MT, Avvisati G, Tribalto, et al: Waldenstrom's macroglobulinemia: Results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 226:443-447, 1989
64. Weber DM, Dimopoulos MA, Delasalle K, et al: 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 30:243-247, 2003
65. Dimopoulos MA, Hamilos G, Efstathiou E, et al: Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophospharnide. Leuk Lymphoma 44:993-996, 2003
66. Leblond V, Tamburini J, Levy V, et al: Treatment of Waldenstrom macroglobulinemia with the combination of fludarabine and cyclophosphamide: Results in 49 patients. 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 55
67. Desikan R, Dhodapkar M, Siegel D, et al: High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 105:993-996, 1999
68. Anagnostopoulos A, Dimopoulos MA, Aleman A, et al: High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 27:1027-1029, 2001
69. Tournilhac O, Leblond V, Tabrizi R, et al: Transplantation in Waldenstrom's macroglobulinemia: The French experience. Semin Oncol 30:291-296, 2003
70. Dreger P, Stilgenbauers S, Seyfarth B, et al: Autologous and allogeneic stem cell transplantation for treatment of Waldenstrom's macroglobulinemia. 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 70
71. Fassas A, Dhodapkar M, Mc Coy J, et al: Management of Waldenstrom's macroglobulinemia in the pre-rituximab era: Update on US Intergroup Trial 59003 and the Arkansas autotransplant experience. 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 59
72. Martino R, Shah A, Romero P: Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant 23:747-749, 1999
73. Maloney DG, Sandmaier BM, Maris M, et al: Allogeneic hematopoietic cell transplantation for refractory Waldenstrom's macroglobulinemia: Replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood 102:472b, 2003 (abstr)
74. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
75. Leonard JP, Link BK: Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 29:81-86, 2002 (suppl 2)
76. Osterborg A, Dyer MJS, Buyes D, et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15:1567-1574, 1997
77. Treon SP, Kelliher A, Keele B, et al: Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations. Semin Oncol 30:248-252, 2003
78. Treon SP, Shima Y, Preffer FI, et al: Treatment of plasma cell dyscrasias with antibody-mediated immunotherapy. Semin Oncol 26:97-106, 1999 (suppl 14)
79. Byrd JC, White CA, Link B, et al: Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity. Ann Oncol 10:1525-1527, 1999
80. Weber DM, Gavino M, Huh Y, et al: Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia. Blood 94:125a, 1999 (abstr 551)
81. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
82. Treon SP, Agus DB, Link B, et al: CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 24:272-279, 2001
83. Dimopoulos MA, Zervas C, Zomas A, et al: Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20:2327-2333, 2002
84. Dimopoulos MA, Zervas K, Zomas A, et al: Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression. Leuk Lymphoma 45:2057-2061, 2004
85. Treon SP, Emmanouilides CA, Kimby E, et al: Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 16:132-138, 2005
86. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45:2047-2055, 2004
87. Ghobrial IM, Fonseca R, Greipp PR, et al: The initial "flare" of IgM level after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia: An Eastern Cooperative Oncology Group Study. Blood 102:448a, 2003 (abstr)
88. Treon SP, Branagan AR, Hunter Z, et al: Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia, Ann Oncol 15:1481-1483, 2004
89. Treon SP, Hansen M, Branagan AR, et al: Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical responses to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol (in press)
90. Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 52:1701-1704, 1999
91. Berentsen S, Ulvestad E, Gjertsen BT, et al: Rituximab for primary chronic cold agglutinin disease: A prospective study of 37 courses of therapy in 27 patients. Blood 103:2925-2928, 2004
92. Sansonno D, De Re V, Lanletta G, et al: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818-3826, 2003
93. Zaja F, De Vita S, Mazzaro C, et al: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827-3834, 2003
94. Treon SP, Branagan A, Wasi P, et al: Combination therapy with rituximab and fludarabine in Waldenstrom's macroglobulinemia. 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 27
95. Hensel M, Villalobos M, Kornacker M, et al: Pentostatin, cyclophosphamide and rituximab: An effective regimen for patients with Waldenstrom's macroglobulinemia. 3rd International Workshop in Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 58
96. Owen RG, Rawstron AC, Osterborg A, et al: Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia. Blood 102:644a, 2003 (abstr)
97. Santos D, Hunter Z, Branagan A, et al: Campath-1H in Waldenstrom's macroglobulinemia. 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 68
98. Rotoli B, De Renzo A, Frigeri F, et al: A phase II trial on alpha-interferon effect in patients with monoclonal IgM gammopathy. Leuk Lymphoma 13:463-469, 1994
99. Legouffe E, Rossi JF, Laporte JP, et al: Treatment of Waldenstrom's macroglobulinemia with very low doses of alpha interferon. Leuk Lymphoma 19:337-342, 1995
100. Ferri C, Marzo E, Longohubardo G, et al: Interferon-alpha in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial. Blood 81:1132-1136, 1993
101. Dimopoulos MA, Zomas A, Viniou NA, et al: Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 19:3596-3601, 2001
102. Coleman M, Leonard J, Lyons L, et al: Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide and dexamethasone. Semin Oncol 30:270-274, 2003
103. Dimopoulos MA, Tsatalas C, Zomas A, et al: Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 30:265-269, 2003
104. Treon S, Hunter Z, Santos D, et al: Thalidomide and rituximab in Waldenstrom's macroglobulinemia. 3rd International Workshop in Waldenstrom's Macroglobulinemia, Paris, France, October, 2004 p 65
105. Mitsiades CS, Mitsiades N, Richardson PG, et al: Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol 30:309-312, 2003
106. Goy AG, Younes A, Mc Laughilin P, et al: A phase II study of proteasome inhibitor bortezomib in relapsed or refractory indolent or aggressive B-cell non-Hodgkin's lymphoma. Hematology J 5:S204-S205, 2004 (suppl 2)
107. Frankel S: Oblimersen sodium (G 3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia. Semin Oncol 30:300-304, 2003
108. Nichols GL, Stein CA: Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides. Semin Oncol 30:297-299, 2003
109. Gertz M, Ceyer S, Kahl B, et al: A phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. 3rd International Workshop in Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 73
110. Treon SP, Tournilhac O, Branagan AR, et al: Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma 5:205-207, 2004
111. Dhodapkar M: Dendritic cell-mediated immunization in macroglobulinemia. Semin Oncol 30:305-308, 2003
112. Gertz MA, Anagnostopoulos A, Anderson K, et al: Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:121-126, 2003
113. Tsai DE, Maillard I, Downs LH, et al: Use of iodine 131 I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia. Leuk Lymphoma 45:591-595, 2004